Alzheon Inc. Company Profile

11:02 EDT 23rd March 2018 | BioPortfolio

Alzheon, Inc. is committed to developing innovative medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders. Our lead clinical candidate, ALZ-801, is a first-in-class, oral inhibitor of amyloid aggregation and neurotoxicity - hallmarks of Alzheimer’s disease. ALZ-801 is an optimized, novel prodrug that builds on the established safety and efficacy profile of the active compound in clinical trials of more than 2,000 patients. Our mission is to apply our discovery platform and development experience to unlock new classes of therapeutics that make a difference in patients’ lives by directly addressing the underlying pathology of devastating neurodegenerative disorders.

News Articles [15 Associated News Articles listed on BioPortfolio]

Alzheon Files for IPO to Fund Studies of Amyloid Alzheimer’s Drug

Alzheon is turning to the public markets to finance a new round of testing for its experimental Alzheimer’s disease drug. The Framingham, MA, company set a preliminary $80 million target for its ini...

Positive safety and efficacy for Alzheon Alzheimer’s candidate

US biotech firm Alzheon has announced the publication of clinical results demonstrating that ALZ-801…

Alzheon's Alzheimer's disease drug fast-tracked by FDA

The FDA granted fast-track designation to Alzheon's oral anti-amyloid drug ALZ-801, which is indicated to treat patients with -More- 

Alzheon Launches IPO to Fund Alzheimer's Drug

Alzheon hopes to raise about $80 million, which will help fund two Phase III clinical trials for its ALZ-801 for Alzheimer’s disease.

FDA Grants Fast Track Designation to Alzheon’s Investigational Alzheimer’s Disease Drug

FRAMINGHAM, Mass.–(BUSINESS WIRE)–Alzheon, Inc., a clinical stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease (AD) and o...

Alzheon IPO To Fund New Phase III Trialling Of Failed Alzheimer's Drug

Alzheon tells prospective investors it believes beta-amyloid blocker ALZ-801 can succeed in pivotal trials by treating APOE4 subgroup.   

The Alzheon IPO Will Fail

Alzheimer's play Alzheon files for IPO

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [2 Associated Companies listed on BioPortfolio]

Alzheon, Inc.

Alzheon, Inc., is a clinical-stage biotechnology company focused on brain health, memory and aging, developing innovative treatments for Alzheimer’s disease and other neurode...

Alzheon Inc.

Alzheon, Inc. is committed to developing innovative medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders. Our lead clini...

More Information about "Alzheon Inc." on BioPortfolio

We have published hundreds of Alzheon Inc. news stories on BioPortfolio along with dozens of Alzheon Inc. Clinical Trials and PubMed Articles about Alzheon Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Alzheon Inc. Companies in our database. You can also find out about relevant Alzheon Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topics

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...

Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...

Corporate Database Quicklinks

Searches Linking to this Company Record